/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | CUVLClinuvel Pharmaceuti |
|---|---|
| Last close | $5.18close 2026-11-09 |
| Change % | +1.57%close 2026-11-09 |
| Market cap | $261Mclose 2026-11-09 |
| P/E | 11.3FY to 2026-06-30 |
| Revenue | $64M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 5.2%FY to 2026-06-30 |
| Net income | $23M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2026-06-30 Filing20-F · 0001493152-26-049364 · filed 2026-10-30 Open the filing on EDGAR →Open the XBRL payload →CiteClinuvel Pharmaceuticals Ltd (CUVL), us-gaap:NetIncomeLoss: 23,177,834 USD, fiscal year ended 2026-06-30. Form 20-F, accession 0001493152-26-049364, filed 2026-10-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001290877/us-gaap/NetIncomeLoss.json |
| Net margin | 36.0%FY to 2026-06-30 |
| EPS (diluted) | $0.46⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2026-06-30 Filing20-F · 0001493152-26-049364 · filed 2026-10-30 Open the filing on EDGAR →Open the XBRL payload →CiteClinuvel Pharmaceuticals Ltd (CUVL), us-gaap:EarningsPerShareDiluted: 0.46 USD per share, fiscal year ended 2026-06-30. Form 20-F, accession 0001493152-26-049364, filed 2026-10-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001290877/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 5FY to 2026-06-30 |
| Altman Z-ScoreUNVALIDATED | 12.52FY to 2026-06-30 |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | — |